复方斑蝥胶囊治疗非小细胞肺癌的网络药理学研究  

Network Pharmacology-Based Study of Compound Banmao Capsules in the Treatment of Non-small Cell Lung Cancer

作　　者：王静[1] 杨志华 易宣洪 李淑静 王志武[1] 汪萍[1] WANG Jing;YANG Zhihua;YI Xuanhong;LI Shujing;WANG Zhiwu;WANG Ping(Tangshan People's Hospital,Tangshan 063000,China;First Teaching Hospital of Tianjin University of TCM,Tianjin 300381,China)

机构地区：[1]唐山市人民医院,河北唐山063000 [2]天津中医药大学第一附属医院,天津300381

出　　处：《西部中医药》2023年第3期28-34,共7页Western Journal of Traditional Chinese Medicine

基　　金：国家自然科学基金青年基金(81603475);唐山市科技计划项目(19150228E)。

摘　　要：目的:基于网络药理学方法探讨复方斑蝥胶囊治疗非小细胞肺癌(non-small cell lung cancer,NSCLC)的作用机制。方法:从中药系统药理学数据库与分析平台(traditional Chinese medicine systems pharmacology database and analysis platform,TCMSP)筛选复方斑蝥胶囊中11味中药的活性成分及作用靶点,利用药物靶标数据库TTD、人类基因数据库(the human gene database,GeneCards)、美国国家生物技术信息中心(NCBI)筛选NSCLC相关靶点基因,通过STRING数据库对疾病与药物共同靶点构建蛋白-蛋白相互作用(PPI)网络模型,运用Cytoscape 3.5.1软件构建化合物-关键靶点相互作用网络图,利用DAVID6.8数据库对共同靶点进行生物过程和信号通路富集分析。结果:共筛选出复方斑蝥胶囊的210种活性成分和310个作用靶点,与治疗NSCLC相关靶点155个,关键靶点68个,主要通过作用于丝氨酸/苏氨酸特异性蛋白激酶1、肿瘤蛋白质53、血管内皮生长因子A、白细胞介素6、促分裂原活化蛋白激酶3、胱天蛋白酶3、JUN激酶、髓细胞增生原癌基因、肿瘤坏死因子、促分裂原活化蛋白激酶1、促分裂原活化蛋白激酶8、信号转导因子和转录激活因子3(急性期应答因子)、表皮生长因子、前列腺素内过氧化物合成酶2(前列腺素G/H合成酶和环氧酶)、雌激素受体1关键靶蛋白调控癌症通路、PI3K-Akt信号通路、癌症中的蛋白多糖通路、NSCLC通路等发挥治疗NSCLC的作用。结论:复方斑蝥胶囊可能通过多靶点、多途径治疗NSCLC。Objective:To explore the mechanism of compound Banmao capsules in the treatment of NSCLC based on network pharmacology method.Methods:The active ingredients and targets of 11 herbs of compound Banmao capsules were screened from TCMSP,NSCLC-related target genes were screened by utilizing TTD,GeneCards and NCBI,PPI network models of disease-medicine common targets were constructed by adopting STRING database,the interaction network diagram of compound-key targets was constructed by using Cytoscape 3.5.1 software,biological process and signaling pathway enrichment analysis of common targets were carried out by utilizing DAVID6.8 database.Results:A total of 210 active ingredients and 310 targets were screened from compound Banmao capsules,155 targets related to NSCLC and 68 key targets,the prescription could treat NSCLC by regulating cancer pathway,PI3K-Akt signaling pathway,proteoglycan pathway in cancer,NSCLC pathway,mainly via acting on AKT1,TP53,VEGFA,IL-6,MAPK3,CASP3,JUN,MYC,TNF,MAPK1,MAPK8,STAT3,EGF,PTGS2 and ESR1 key target proteins.Conclusion:Compound Banmao capsules could treatment of NSCLC from many targets and pathways.

关 键 词：非小细胞肺癌 信号通路 生物过程 网络药理学 复方斑蝥胶囊 作用机制 

分 类 号：R734.2[医药卫生—肿瘤]